title: Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.
abstract: We evaluated serum leptin levels in 9 young chronic myeloid leukemia (CML) patients under imatinib therapy during a long-term follow-up. Body mass index (BMI) and fat mass percentage (%FM) were also measured. Leptin was above the normal range in 8 out of 9 patients. In one case the hormone was below the reference value. All subjects showed a normal BMI, but 3 had a small increase of FM%. One patient recovered the leptin normal value after imatinib suspension. A tendency to leptin normalization in patients switched to an intermittent therapy was also found. This study suggests that imatinib therapy may result in leptin alteration.
authors.affiliation: Department of Experimental Medicine, Sapienza University of Rome, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Mariani
authors.affiliation: Department of Experimental Medicine, Sapienza University of Rome, Italy.
authors.forename: Sabrina
authors.initials: S
authors.lastname: Basciani
authors.affiliation: Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Italy.
authors.forename: Fiorina
authors.initials: F
authors.lastname: Giona
authors.affiliation: Department of Experimental Medicine, Sapienza University of Rome, Italy.
authors.forename: Carla
authors.initials: C
authors.lastname: Lubrano
authors.affiliation: Department of Experimental Medicine, Sapienza University of Rome, Italy.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Ulisse
authors.affiliation: Department of Experimental Medicine, Sapienza University of Rome, Italy.
authors.forename: Lucio
authors.initials: L
authors.lastname: Gnessi
keywords: Chronic myeloid leukemia; Imatinib; Leptin